Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: IV iron Clear all

Conditions: Chronic Kidney Disease (CKD)
Interventions: Epoetin Hospira Arm, Standard of Care Arm, IV Iron; Biological · Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 42
States / cities: Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more

Conditions: Anemia
Interventions: Venofer; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Inflammation
Interventions: Adenosine, Sodium Nitroprusside; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Familial Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm
Interventions: Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 103
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more

Conditions: Iron Deficiency, Fibromyalgia
Interventions: Injectafer, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Anemia
Interventions: Venofer; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Anemia, Iron Deficiency, Uterine Bleeding
Interventions: Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric], Ferrous Sulfate 65 mg elemental iron (325 mg tablets); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: IDA - Iron Deficiency Anemia, Anemia, Iron Deficiency Anemia, Anemia, Iron Deficiency
Interventions: Ferric derisomaltose, NovaFerrum; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 16 Years to 60 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Duarte, California • Los Angeles, California

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions: Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 16
States / cities: Los Angeles, California • Sacramento, California • Santa Ana, California + 9 more

Conditions: Hereditary Hemorrhagic Telangiectasia
Interventions: Feraheme MRI/MRA; Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Iron Deficiency Anemia
Interventions: Ferric carboxymaltose, Ferrous Sulfate; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 16
States / cities: Little Rock, Arkansas • Doral, Florida • Miami, Florida + 10 more

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 114
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 83 more

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 141
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, FCM; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 100
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 83 more

Conditions: Chronic Heart Failure, Iron Deficiencies
Interventions: Ferric Derisomaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Bone Cancer, Chondrosarcoma, Ewing's Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Bone Necrosis, Bone Sarcoma, Osteomyelitis
Interventions: Feraheme, Magnetic Resonance Imaging (MRI) scan; Drug · Procedure
Lead sponsor: Heike E Daldrup-Link; Other
Eligibility: 10 Years to 21 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: IDH Wild Type Glioblastoma
Interventions: ¹⁸F-Fluoromisonidazole, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Oxygen Therapy, Ferumoxytol, Gadolinium; Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Kidney Disease, Iron-deficiency Anemia
Interventions: IV Iron, Ferrous Sulfate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions: Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements; Drug
Lead sponsor: University of Washington; Other
Eligibility: Up to 3 Days
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, Placebo; Drug · Other
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 137
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 105 more

Conditions: Iron-refractory, Iron-deficiency Anemia (IRIDA)
Interventions: Triferic, Fer-In-Sol, Shohl's solution; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Iron Deficiency Anemia, Pregnancy
Interventions: Ferric derisomaltose, Ferrous sulfate; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more

Conditions: Hypotension
Interventions: Nitroprusside; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

Role of Adenosine in the Release of VEGF and Cytokines

DCE MRI in Patients With Pancreatic Cancer

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients

IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department

Iron Deficiency Anemia (IDA) and the Brain

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

MRA With Feraheme in HHT

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Feasibility of FMISO in Brain Tumors

A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia

Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room